<div id="readability-page-1"><div><p>Health-care companies rose as traders sought out evergreen sectors in light of recent volatility.</p><p>    Shares of Eli Lilly rose, and the maker of Zepbound and other obesity drugs became the first pharmaceutical company to hit $1 trillion in market capitalization. </p><p>    British drugmaker GSK and U.S. biotechnology company AnaptysBio are suing one another, with dueling allegations about breaching a licensing agreement for cancer treatment Jemperli. </p><p>   Write to Rob Curran at rob.curran@dowjones.com </p><p>    (END) Dow Jones Newswires</p><p>11-21-25 1734ET</p></div></div>

禮來

葛蘭素史克

<p>醫療保健公司因交易者在近期波動中尋求穩定的行業而上漲。禮來的股票上漲，該公司生產的 Zepbound 和其他肥胖藥物使其成為首家市值達到 1 萬億美元的製藥公司。英國製藥公司葛蘭素史克與美國生物技術公司 AnaptysBio 相互起訴，雙方就癌症治療藥物 Jemperli 的許可協議違反問題展開激烈爭論。請聯繫 Rob Curran，郵箱為 rob.curran@dowjones.com (完) 道瓊斯新聞社 11-21-25 1734ET</p>

醫療保健板塊上漲，因交易員尋求投資於常青行業——醫療保健綜述